{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:44Z","timestamp":1787070884801,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Targeting MUC1 antigens which are overexpressed in 80% of breast cancers can be widely used in the field of radioimmunoscintigraphy (RIS) of breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The aim of this study was to develop a new diagnostic labeled compound for breast cancer RIS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design:<\/jats:title>\n                    <jats:p>In this study, an efficient indirect labeling method of PR81 with Indium-111 was developed and preliminary preclinical qualifications were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>111<\/jats:sup>\n                      In-DTPA-PR81 was prepared and its radiochemical purity and stabilities in human serum and in phosphate-buffered saline (PBS) buffer were surveyed. Furthermore, cellular studies including complex reactivity, binding specificity, cell toxicity, etc., were examined. Finally, biodistribution and scintigraphy of the complex were studied in normal and tumoral animals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis Used:<\/jats:title>\n                    <jats:p>Statistical analyses were performed using SPSS 10.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>111<\/jats:sup>\n                      In-DTPA-PR81 was prepared with a radiochemical purity of &gt;99% at optimized conditions. Stability studies showed the radiochemical purity of &gt;90% in PBS buffer after 96 h, while the stability in human serum showed decrement to 81% after 96 h. Reactivity of the complex with MUC1 was significantly (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.005) higher than bovine serum albumin (BSA) (about 7\u20138 times), even though BSA concentration was about twice the MUC1. The binding specificity of the complex to the MUC1 antigen was confirmed by means of immunoreactivity assay. Cell toxicity examination showed no significant lethal effect of the radiolabeled compound on the cells. Biodistribution studies of the complex in normal rats were consistent with the biodistribution of antibodies and high accumulation was observed in the tissues expressing MUC1 antigen. The results of\n                      <jats:sup>111<\/jats:sup>\n                      In-DTPA-PR81 scintigraphy in tumoral female BALB\/c mice at 24 and 48 h after injection showed an increasement of the accumulation in the tumor site.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>111<\/jats:sup>\n                      In-DTPA-PR81 can be considered as a potential agent for imaging of the MUC1 +breast tumors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_730_20","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T10:31:54Z","timestamp":1674815514000},"page":"158-167","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Preparation and preclinical characterization of 111 In-DTPA-Anti-MUC1 as a radioimmunoconjugate for diagnosis of breast cancer by single-photon emission computed tomography"],"prefix":"10.4103","volume":"18","author":[{"given":"Behrouz","family":"Alirezapour","sequence":"first","affiliation":[{"name":"Department of Radioisotopes and Radiopharmaceuticals, Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood Dehghani","family":"Ashkezari","sequence":"additional","affiliation":[{"name":"Department of Biology, Islamic Azad University, Ashkezar Branch, Yazd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi Memari","family":"Fini","sequence":"additional","affiliation":[{"name":"Department of Biology, Islamic Azad University, Ashkezar Branch, Yazd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Rasaee","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, School of Medical Siences, Tarbiat Modares University (TMU), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Mohammadnejad","sequence":"additional","affiliation":[{"name":"Department of Life Science Engineering, Faculty of New Sciences & Technologies, University of Tehran, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malihe","family":"Paknejad","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Maadi","sequence":"additional","affiliation":[{"name":"Department of Radioisotopes and Radiopharmaceuticals, Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Yousefnia","sequence":"additional","affiliation":[{"name":"Department of Radioisotopes and Radiopharmaceuticals, Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Zolghadri","sequence":"additional","affiliation":[{"name":"Department of Waste Management, Materials and Fuel Cycle Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"R2-20250510","first-page":"CD001877","article-title":"Screening for breast cancer with mammography","volume":"6","author":"G\u00f8tzsche","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R3-20250510","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/00006231-199708000-00003","article-title":"Scintigraphic imaging of breast cancer: A review","volume":"18","author":"Buscombe","year":"1997","journal-title":"Nucl Med Commun"},{"key":"R4-20250510","doi-asserted-by":"crossref","first-page":"283","DOI":"10.6061\/clinics\/2013(03)OA01","article-title":"99mTc-thymine scintigraphy may be a promising method in the diagnosis of breast cancer","volume":"68","author":"Ribeiro","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"R5-20250510","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/s00259-004-1525-x","article-title":"Breast scintigraphy today: Indications and limitations","volume":"31","author":"Schillaci","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20250510","first-page":"52","article-title":"Role of scintimammography in the diagnosis of breast cancer","volume":"13","author":"Das","year":"2006","journal-title":"Malays J Med Sci"},{"key":"R7-20250510","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0002-9610(03)00077-1","article-title":"International prospective evaluation of scintimammography with (99m) technetium sestamibi","volume":"185","author":"Sampalis","year":"2003","journal-title":"Am J Surg"},{"key":"R8-20250510","first-page":"48","article-title":"Radioimmunoscintigraphy of breast cancer","volume":"2","author":"Salouti","year":"2017","journal-title":"Cell Immunol Serum Biol"},{"key":"R9-20250510","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/bcr3167","article-title":"In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores","volume":"14","author":"Sano","year":"2012","journal-title":"Breast Cancer Res"},{"key":"R10-20250510","first-page":"103","article-title":"Monoclonal antibodies: Old and new trends in breast cancer imaging and therapeutic approach","volume":"8","author":"Stipsanelli","year":"2005","journal-title":"Hell J Nucl Med"},{"key":"R11-20250510","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4161\/cbt.6.4.4201","article-title":"MUC1: A target molecule for cancer therapy","volume":"6","author":"Singh","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"R12-20250510","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tranon.2016.05.001","article-title":"Antibody-guided in vivo imaging for early detection of mammary gland tumors","volume":"9","author":"Moore","year":"2016","journal-title":"Transl Oncol"},{"key":"R13-20250510","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/IJN.S118482","article-title":"Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: Initial considerations","volume":"12","author":"do Carmo","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"R14-20250510","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/153685903322286566","article-title":"Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin","volume":"22","author":"Paknejad","year":"2003","journal-title":"Hybrid Hybridomics"},{"key":"R15-20250510","first-page":"7","article-title":"99mTc direct radiolabeling of PR81, a new anti-MUC1 monoclonal antibody for radioimmunoscintigraphy","volume":"13","author":"Salouti","year":"2005","journal-title":"Iran J Nucl Med"},{"key":"R16-20250510","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.nucmedbio.2008.07.002","article-title":"Breast tumor targeting with (99m)Tc-HYNIC-PR81 complex as a new biologic radiopharmaceutical","volume":"35","author":"Salouti","year":"2008","journal-title":"Nucl Med Biol"},{"key":"R17-20250510","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/HAB-2010-0216","article-title":"Radioimmunotherapy of MCF7 breast cancer cell line with {131} I-PR81 monoclonal antibody against MUC1: Comparison of direct and indirect radioiodination methods","volume":"13","author":"Mohammadnejad","year":"2010","journal-title":"Hum Antibodies"},{"key":"R18-20250510","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nucmedbio.2015.07.012","article-title":"Development of [64Cu]-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging","volume":"43","author":"Alirezapour","year":"2016","journal-title":"Nucl Med Biol"},{"key":"R19-20250510","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-1-4939-0363-4_9","article-title":"Antibody labeling with radioiodine and radiometals","volume":"1141","author":"Gupta","year":"2014","journal-title":"Methods Mol Biol"},{"key":"R20-20250510","first-page":"155","article-title":"Indium-111 satumomab pendetide: The first FDA-approved monoclonal antibody for tumor imaging","volume":"26","author":"Bohdiewicz","year":"1998","journal-title":"J Nucl Med Technol"},{"key":"R21-20250510","first-page":"1200","article-title":"111In-labeled N-cadherin antibody for cancer imaging using single-photon emission computed tomography","volume":"57","author":"Zhang","year":"2016","journal-title":"J Nucl Med"},{"key":"R22-20250510","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3892\/or.2017.5412","article-title":"Uptake of 111In-labeled fully human monoclonal antibody TSP-A18 reflects transferrin receptor expression in normal organs and tissues of mice","volume":"37","author":"Sugyo","year":"2017","journal-title":"Oncol Rep"},{"key":"R23-20250510","first-page":"1351","article-title":"First-in-human phase 0 study of 111in-chx-a\u201d-trastuzumab for her2 tumor imaging","volume":"57","author":"Kurdziel","year":"2016","journal-title":"J Nucl Med"},{"key":"R24-20250510","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3390\/molecules19022135","article-title":"Radiolabeling strategies for tumor-targeting proteinaceous drugs","volume":"19","author":"Sugiura","year":"2014","journal-title":"Molecules"},{"key":"R25-20250510","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1042\/BA20040121","article-title":"Continuous production of monoclonal antibody in a packed-bed bioreactor","volume":"41","author":"Golmakany","year":"2005","journal-title":"Biotechnol Appl Biochem"},{"key":"R26-20250510","first-page":"355","article-title":"Production and quality control of [67Ga]-DOTA-trastuzumab for radioimmunoscintigraphy","volume":"12","author":"Alirezapour","year":"2013","journal-title":"Iran J Pharm Res"},{"key":"R27-20250510","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/0973-1482.131434","article-title":"Preclinical evaluation of [111In]-DOTA-trastuzumab for clinical trials","volume":"10","author":"Alirezapour","year":"2014","journal-title":"J Cancer Res Ther"},{"key":"R28-20250510","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","article-title":"Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess","volume":"72","author":"Lindmo","year":"1984","journal-title":"J Immunol Methods"},{"key":"R29-20250510","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.nucmedbio.2008.09.001","article-title":"Evaluation of novel bifunctional chelates for the developments of Cu-64-based radiopharmacuticals","volume":"35","author":"Ferreira","year":"2008","journal-title":"Nucl Med Biol"},{"key":"R30-20250510","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bbagen.2010.02.002","article-title":"Radiolabelled protein for positron emission tomography: Pros and cons of labeling methods","volume":"1800","author":"Tolmachev","year":"2010","journal-title":"Biochimic Biophysic Acta"},{"key":"R31-20250510","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0969-8051(03)00019-2","article-title":"Targeting of renal carcinoma with 67\/64Cu-labeled anti-L1-CAM antibody chCE7: Selection of copper ligands and PET imaging","volume":"30","author":"Zimmermann","year":"2003","journal-title":"Nucl Med Biol"},{"key":"R32-20250510","first-page":"8498","article-title":"Stage- and tissue-specific expression of the HER2\/neu oncogene in rat development","volume":"84","author":"Kokai","year":"1987","journal-title":"Develop Biol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_730_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:15Z","timestamp":1787067495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_730_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_730_20","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2020-05-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}